White Paper
Adoption of Anonymization for Innovation thumbnail

Adoption of Anonymization for Innovation

Recent regulations from Canada and the European Union surrounding data transparency in clinical trials have brought transparency standards and technology to the forefront for pharmaceutical companies. Last year, d-wise kicked off new research with pharmaceutical companies and contract research organizations on readiness for data transparency. Our findings are included in this whitepaper.

Objectives of our research included:

  • Determine the state of transparency adoption processes
  • Assess how sponsors plan on meeting regulatory deadlines, both currently and in future
  • Identify pain points around data transparency


View All White Papers